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Abstract
Background: As the number of randomised controlled trials of medicines for children increases,
it becomes progressively more important to understand the experiences of parents who are asked
to enrol their child in a trial. This paper presents a narrative review of research evidence on
parents' experiences of trial recruitment focussing on qualitative research, which allows them to
articulate their views in their own words.
Discussion: Parents want to do their best for their children, and socially and legally their role is
to care for and protect them yet the complexities of the medical and research context can
challenge their fulfilment of this role. Parents are simultaneously responsible for their child and
cherish this role yet they are dependent on others when their child becomes sick. They are keen
to exercise responsibility for deciding to enter a child in a trial yet can be fearful of making the
'wrong' decision. They make judgements about the threat of the child's condition as well as the risks
of the trial yet their interpretations often differ from those of medical and research experts.
Individual parents will experience these and other complexities to a greater or lesser degree
depending on their personal experiences and values, the medical situation of their child and the
nature of the trial. Interactions at the time of trial recruitment offer scope for negotiating these
complexities if practitioners have the flexibility to tailor discussions to the needs and situation of
individual parents. In this way, parents may be helped to retain a sense that they have acted as good
parents to their child whatever decision they make.
Summary: Discussing randomised controlled trials and gaining and providing informed consent is
challenging. The unique position of parents in giving proxy consent for their child adds to this
challenge. Recognition of the complexities parents face in making decisions about trials suggests
lines for future research on the conduct of trials, and ultimately, may help improve the experience
of trial recruitment for all parties.
Background
When parents are asked to consider enrolling their child
in a paediatric clinical trial their primary responsibility is
the best interests of their child. This role is very different
to an adult deciding about their own participation in a
trial, whose role involves exercising individual autonomy
[1]. Grappling with complex, medical information is
always part of trial decision making but when this is on
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serve one's own rights and interests, the decision will
likely feel more serious and possibly overwhelming.
Despite this fundamental difference between trials in
adult and paediatric medicine, relatively little is known
about how the particular role of parents influences the
communication about a trial. Insight into this is impor-
tant if we are to improve families' experiences of trial
recruitment, as well as optimise enrolment procedures
and suggest appropriate directions for future research.
In this paper we will argue that when parents are
approached about a trial for their child, the decision is
influenced by particular considerations and requires spe-
cial management. We will discuss evidence on the com-
plex experience of parents when considering trial entry for
their child, what trials mean to them and what contextual
factors impact on their experience of decision making. We
have drawn primarily on studies which have a qualitative
design, though we have included a wider body of evidence
where it offered useful insights. Studies using qualitative
methodology were specifically targeted because they
access participants' accounts in their own words, allowing
more scope to explore their meanings and experiences
and making fewer assumptions about what is important
to them [2].
This discussion does not aim to make specific recommen-
dations for how to discuss randomised clinical trials with
parents, rather its intention is to increase awareness of
how parents make sense of trials and suggest directions for
future research to improve the experience of recruitment
to trials from the perspective of all parties involved.
Discussion
Vulnerability, responsibility and regret
For parents the diagnosis of serious illness in a child can
be a shattering experience [3]. When consent is sought
soon after diagnosis, parents will be making decisions
when they are distressed and vulnerable [4-6], whilst
simultaneously trying to comfort their sick child. Being
approached about a trial confronts parents with a volume
and complexity of information well beyond their every-
day experience and they can never be certain about what
is the 'right' decision. However, whilst they may be vulner-
able, protecting their child is fundamental to the parental
role and this will shape how they think about trials. Par-
ents in one study felt personally and directly accountable
for their child's outcome on a trial and thought that giving
consent for a child would be much more difficult than
deciding to take part in a trial themselves [7]. Survey evi-
dence confirms that the responsibility to act in the best
interests of one's child is keenly felt, with one third of par-
ents in one study reporting that while they might accept
certain research risks for themselves they were much less
certain about accepting the same risks for their baby [8].
The sense of responsibility that accompanies parents'
decision making about trials may paradoxically render
them more vulnerable, especially to the anticipation of
regret [9]. Mothers whose children were enrolled into a
bone marrow transplant trial dreaded the possibility that
they might have to live with the knowledge that they had
made the 'wrong' decision and this was intensified when
things did not go well for the child [10]. Mothers of chil-
dren with leukaemia [11] felt highly dependent on clini-
cians and experienced considerable unease in making
decisions about trials with little grasp of the disease. Peo-
ple are motivated to avoid regret by making decisions that
minimise its likelihood [12] and the more important the
outcome, the greater the anticipation of regret particularly
if the outcome is irreversible [13]. In view of the roles and
responsibilities of parenthood, the anticipation of regret
about potentially 'failing to protect' one's child may be a
major influence on parents' decisions about trials. Canvin
and colleagues speculate that the sense of responsibility
surrounding the trial decisions of parents of children with
epilepsy was eased by the voluntary and reversible nature
of the decision [14]. However, when things do go wrong,
people experience more regret for acts of commission
(doing) than for acts of omission (not doing) [15], and
think more about harm caused by direct action than about
indirect harm [9]. Therefore, parents may hesitate to vac-
cinate their child even under conditions where the likeli-
hood of a fatal side effect is only a fraction of the death
rate from the disease [16], presumably because antici-
pated regret looms larger for the act of vaccination. As yet
no research has looked at whether parents respond in the
same way to trial participation – rationalising that not
participating minimises the chance of regret and is the
'safest' option.
Understandings of events can, of course, be retrospec-
tively shaped and reconstructed to manage regret. Parents
who consented their child to enter the ECMO trial [17]
constructed randomisation as offering protection from
responsibility should the child have a poor outcome. This
protection could be extended to doctors, who in the eyes
of some parents could not be held responsible when there
was uncertainty as to the best treatment. Some families
constructed their views about which is the 'best' arm of the
trial based around which arm they were allocated to – for
example, some who were allocated to conventional treat-
ment focussed on the likelihood that this avoided the
risks associated with the treatment arm and need for trans-
fer to another unit [17].
Recognising this difficult situation for parents, the incom-
patibility of wanting to do what is best for the child butPage 2 of 11
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ical in understanding how parents respond to clinical tri-
als. What may seem to the trialist as a misunderstanding
of trial rationale may be the parent constructing the situa-
tion in a way which is acceptable to their need to protect
their child.
The parental role and the function of consent
Decisions about trial entry may be a source of intense
emotional strain for parents but being offered options
about their child's treatment and research participation is
likely to serve important psychological functions, particu-
larly at times when there is little else parents can do instru-
mentally for the child. Parents of children hospitalised for
spinal surgery described the "loss of parental role" and the
accompanying helplessness and frustration they experi-
enced as being of a similar magnitude as their distress
about the potential of poor surgical outcome and watch-
ing their child in pain [18]. The process of consent itself
could function as a symbolic acknowledgement of their
role when there is little else parents can do.
When asked their views on Zelen randomisation (single
consent method), parents whose baby was involved in a
conventionally randomised trial were evenly divided on
its acceptability [19]. With this method, randomisation
takes place prior to discussion with the family. If the child
is allocated to the conventional treatment arm, they are
not informed about the trial. Only if the child is allocated
to the experimental arm is consent sought. In offering
'protection' from the difficulties of trial decision making,
the knowledge that there are treatments which they can-
not access, and from the knowledge that treatment is
determined by chance, this approach might be considered
'kinder' to those families allocated to the conventional
treatment arm. However, Zelen randomisation was
viewed negatively by some parents because they perceived
it as preventing the sense that they were operating in the
best interests of their child. As difficult as the decision on
trial entry was for parents, they felt it was theirs to make
[19]. Similarly, parents who participated in a survey inves-
tigating different types of consent to hypothetical neona-
tal resuscitation trials were more comfortable with
prospective consent than with consent which was
deferred, waived or required the parent to 'opt-out'. They
wanted to be informed about the trial and make the deci-
sion themselves [20]. Other surveys provide further evi-
dence that parents value their role in decisions about trial
entry – over 90% say they do not want the doctor or nurse
to decide on their behalf [21,22,8]. Parents upheld these
views even when they realised that the quality of their
consent was limited or experienced the informed consent
process as an additional burden [23], indicating that con-
sent could indeed serve important symbolic functions.
Research on trials which involve deferred or waived con-
sent [24] could further inform ideas about the social func-
tion of consent and processes of regret, both of which
might be configured rather differently depending on
whether consent is conventional, waived or deferred.
Bioethicists and others have pointed out that informed
consent did not develop to safeguard autonomy, rather its
primary purpose is to preserve well-being [25,26]. All-
mark and Spedding suggest that parental consent for clin-
ical trials is important as a social recognition of the role of
parents, but offers little additional protection for children
to that provided by appropriate research ethics, safety
monitoring and governance procedures. From this posi-
tion the quality of parental consent might be less critical,
and their decision making difficulties could be eased by
knowing about ethics [23] and other research safety and
governance procedures. Of course, this assumes parents
can be confident in the protection offered by research gov-
ernance and monitoring but a recent review suggests that
safety monitoring in paediatric trials may have been inad-
equate in some cases and highlights the need for monitor-
ing of all paediatric trials [27]. At the same time as
wanting the option to decide, parents value doctors'
advice about trials [28] and some look to share responsi-
bility for their decisions with practitioners. In one neona-
tal study three-quarters of parents believed their doctors
would not ask to do research if it might put babies in real
danger [8] and half indicated that they trusted their doctor
and if he or she suggested their baby should enter a trial,
they would agree. Though they have authority for their
child, parents lack expertise in matters related to the
child's illness, and as a consequence, are likely to rely
heavily upon the expertise of medical practitioners.
The role of parents in trial decision making is therefore
complex – they can be simultaneously responsible for
their child and dependent on practitioners. The challenge
for trialists in discussing paediatric trials with parents is to
balance the tensions this brings, so supporting parents'
decision making appropriately and guarding against the
possibility of regret [7]. Research on how this might be
achieved is much needed. The potential for emotional
conflict is apparent in the accounts of parents of babies
receiving treatment on NICU [29], who were united in
wanting to be considered the primary decision-maker for
their baby, but were much less consistent in wishing to be
actively involved in decisions which they viewed as seri-
ous. The authors suggest that asking parents to do so
could carry high 'psychological costs'.
Threat, hope and certainty
The seriousness of the child's condition and the urgency
surrounding trial entry will be important influences on
how parents experience recruitment to trials, their sense of
vulnerability, and the success of communication [23]. InPage 3 of 11
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retain a sense that they have operated in their child's best
interests [30]. Parents considering oncology and neonatal
trials report particularly high levels of distress during trial
discussions and a sense that this impairs their ability to
ask questions or seek additional information [31] occa-
sionally leading them to later doubt their decisions [32].
In these situations the thoughts and emotions of parents
are dominated by the fact that they have a very sick child
[33] or worse, the fear that their child might die [34]. By
contrast, parents of children with less serious chronic ill-
nesses report more comfort in making decisions about
trial entry [32] and in judging what is in the best interests
of the child because they have experience of the disease. It
follows that parents' priorities will vary with the serious-
ness of their child's illness. For example, parents of chil-
dren participating in research on mild to moderate
asthma rated "learn more about disease" as the primary
motivation (from 14 choices) [35]. In chronic childhood
illness, the day to day management of the condition, the
child's quality of life and the simple practicalities of trial
participation may gain importance. This is in marked con-
trast to parents of children whose lives were in the bal-
ance, some of whom struggled even to understand or
recall that research participation was voluntary [10].
Parents' worries and misperceptions provide further
insights into what trials mean to them and point to spe-
cific sources of difficulty in communication. The worry
that their child might be randomized to the less effective
treatment [31] and the responsibility that they would feel
if the child later deteriorated are particularly common [1].
On finding that their child has been allocated to the
standard treatment arm, parents sometimes report a sense
of disappointment or missed opportunity, as if the child
has been deprived of a known beneficial treatment or has
'failed' the selection process. Some mothers felt resent-
ment that they had been asked to go through the trauma
of deciding about trial entry for 'nothing' [11]. Others
viewed randomisation as a way of allocating limited
resources and expressed guilt that their child had been
allocated the experimental arm while others had only
received conventional treatment [17,36]. Founded on a
difficulty in accepting that there is uncertainty about the
effectiveness of trial treatments or an assumption that the
experimental treatment will necessarily be superior, these
responses remind us that in the face of intense threat and
uncertainty, parents look for hope and certainty. In such
circumstances it is not surprising they find the uncertainty
that is intrinsic to trials challenging both cognitively and
emotionally, or that they are liable to construct trial treat-
ments as the answer to their child's needs.
The generally high rates of recruitment to trials in neona-
tology [37] and childhood cancer [38] suggests the level of
threat and parents' consequent needs for hope could be
important influences on how they view trials. Parents of
chronically and terminally ill children stated that they
were prepared to take greater risks in treatment in the
hope of a cure [7]. Similarly, parents' decisions about
Phase 1 cancer trials, which can bring side-effects and
offer little chance of long term medical benefit, may turn
upon a fear of 'giving-up' on their child and the need to
'leave no stone unturned'[39,40]. High recruitment rates
may also be testament to the importance that is deservedly
placed on research in neonatology and childhood cancer
by both parents and trial staff [41,42]. But they could also
be a sign of parents' reluctance to decline a trial where it
involves saying "no" to the clinical team on whom their
child's care depends. By contrast parents of healthy chil-
dren considering participation in vaccine research
believed that children should only take part in research
where the medical benefits outweigh any potential risk
[43]. Work comparing what researchers say and intend
when they discuss trials with parents, and what parents
interpret from these discussions will yield further insights
into the challenges for both parties [44] and how they co-
construct their views of trials and their respective roles.
In deciding about hypothetical research scenarios, parents
and children were more likely to respond intuitively and
emotionally to research information than to systemati-
cally attempt to consider and weight all the available
information. The result was that the 'information' partici-
pants used to underpin their decisions was often very dif-
ferent to the information that the researchers intended
them to use [45]. Participants' emotional responses to
information were shaped by their particular life experi-
ences. Similarly, Chantler and colleagues report that par-
ents who received the same information about a vaccine
study varied widely in their perceptions of the risks of the
trial, with some seeing it as potentially dangerous while
others viewed it as safe with no negative effects. Parents
from a professional background in science or ongoing
experience of medical care were less likely to cite anxiety
and unfamiliarity as a reason for declining the trial, and in
the view of the authors, were more open to research and
better able to judge the trial's importance and value [43].
If the same information can mean different things to dif-
ferent people, clinicians' assessment of risk will also be
influenced by their professional experience, and trial risks
as seen by parents may be very different to those perceived
by trial staff. Moreover, relative risk, a concept familiar to
clinicians accustomed to the uncertainty that is intrinsic to
medical practice, could seem very different to parents for
whom even improbable risks may be intolerable [46].
Parents and investigators agreed that the risks associated
with participation in clinical anaesthesia or surgery
research was the most important information to disclose,Page 4 of 11
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the importance of disclosing the benefits of the research
[47]. One interpretation is that risks resonate more deeply
with parents and they therefore need to balance these with
positive information. Similarly, clinicians viewed the
CANDA trial as a low risk, routine trial of broadly equiva-
lent interventions [48] but many parents consenting to
the trial viewed it as offering an otherwise unavailable
option which might save their baby's life. To the clinician
research can be considered low risk when it involves no
greater risk than conventional treatment. To the parent
everything is high risk because they have a sick child.
The contrast between parents' and clinicians' and trialists'
views warrants further investigation but it is unlikely that
parents always approach decisions about trials in the way
imagined by some – a rational and mechanistic process of
weighing up all of the available information before reach-
ing a decision [45,49]. Associated with a 'rational choice'
model of trial decision-making is the assumption that
communication is a mechanistic and technical matter of
assembling and transmitting the 'correct' information but
successful communication about trials or any other topic
is more than a technical matter [50]. It is a dynamic, social
and emotional process in which the parties interact to
construct meaning. Their interaction will be shaped by the
particular context and nature of the trial, the hopes, fears,
expectations and obligations the parties bring to the trial
discussions, and those that continually emerge during the
course of discussions and in their later reflections.
Individual and group differences in trial perceptions and 
information preferences
Even in life threatening situations, not all parents will
experience trials as adding "stress to an already stressful
situation" [22]. Wide individual differences in parents'
responses to being approached about trials have been
reported with 20% reporting that the trial reduced their
anxiety, 56% felt it made no difference and 24% reporting
that the trial increased their anxiety [51]. Associations
between anxiety and the decisions parents make about tri-
als have also been observed. Parents who decline trials
report higher anxiety, rate the risks of the trial as higher
[52] and are more likely to fear randomisation [53], but
one study found consenting parents were more anxious
than those who declined [54]. Rather than being straight-
forward the relationship between anxiety and trial deci-
sions may be mediated or moderated by factors such as
trust in medical research [55] and the parent-practitioner
relationship [56].
Parents also vary in their preferences for trial information
[57], some wanting more information whilst others feel
overwhelmed by information and want less [58]. Miller
and colleagues reported a trend for more information to
be associated with greater parental anxiety and less con-
trol [59], which may be exacerbated by detailed informa-
tion on the toxic effects of treatment or mortality rates. Of
course, the anxiety experienced by parents will itself
impact on their experience and interpretation of the trial
information and discussion [60]. In one study of parents
of children considering an oncology trial, those with
higher levels of anxiety were more likely to report that the
risks associated with trial entry were not clearly explained
[61]. Getting the level of information right is an important
challenge – one study of parents' attitudes to their child's
enrolment in a trial of antiretroviral therapy reported a
significant relationship between perceiving that informa-
tion was lacking and unwillingness to enrol in future trials
[62]. Similarly Tait and colleagues report that parents who
were more satisfied with the clarity and quantity of trial
information were more positive about the trial than par-
ents who were dissatisfied with the information [63].
Researchers have suggested a 'goodness of fit' approach
between the person and the amount of information given
[64].
Discussions about trial participation may have lasting
effects for those who decline trials as well as those who
accept. Non participants report inaccurate [65] or even
harmful misconceptions [48] after being approached
about research. Those conducting trials need to under-
stand the processes that underpin these difficulties if they
are to be ameliorated. Concern that those who decline or
drop out may come to regret their decision [65] might be
extended to consider how individuals approached about
trials may differ in their tendency to trust others. Evidence
suggests that a substantial minority of people find it diffi-
cult to trust other people [66] and are less likely to per-
ceive relationships with health professionals as supportive
[67]. Such people may be especially at risk of harmful mis-
conceptions if trialists cannot vary their approach accord-
ing to individual needs. Indeed, the assumption that
'good' communication is synonymous with providing
information that is ever more specific or systematic runs
counter to the requirement, in complex discussions about
trials, to select and tailor according to individual need
[59]. There is, of course, a baseline level of information
necessary for informed consent [25]. Beyond this, trialists
and ethicists could consider how far communication
about trials can be configured around the needs and pref-
erences of individual parents [68] as well as the social
norms of the setting [25].
Of the few studies that have considered group differences
in trial recruitment, most have focussed on families of
children with leukaemia. How parents from different
socio-demographic backgrounds experience trials has not
been explored, though researchers have investigated
group differences in rates of trial participation andPage 5 of 11
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leagues [59] report that low socio-economic status (SES)
and membership of a minority ethnic group (in this case
largely Hispanic) was associated with lower understand-
ing of key components of informed consent. A related
study reported no differences in likelihood to enrol a
child in a trial between English speaking majority parents,
English speaking minority parents and non-English
speaking minority parents [69]. Parents in the non-Eng-
lish speaking group asked fewer questions than parents in
the other groups. The authors link this to Latino cultural
norms such as 'respeto' and 'fatalismo' which discourage
questions and interactivity and encourage the idea that
God will decide the fate of the child [70]. Emphasising the
diversity that also exists within different ethnic groups [70]
the authors point out that such traditional values are far
from uniform within Hispanic groups and tend to be less
common in immigrant groups with high SES.
Beyond oncology, research on group differences is lim-
ited. Harth and Thong reported that, among other charac-
teristics, parents who put their child forward for an
asthma trial were less educated and from less advantaged
backgrounds than parents who declined [71] while a
study of factors influencing consent to a neonatal trial
found no such differences [28]. Tait and colleagues [72]
report that greater understanding of 11 key elements of
consent (to clinical anaesthesia or surgery trials) was pos-
itively associated with parents' educational level but not
ethnicity and that understanding was higher in consenters
than non-consenters.
Of course, a parent can only understand and recall infor-
mation if it has been provided in the first place. Miller and
colleagues [59] report that practitioners provided less
information to ethnic minority parents and parents with
low SES and were less likely to ask their opinion or
encourage questions. Simon and colleagues [69] also
found that non English speaking minority groups were
given less information and clarification of features such as
randomisation and right to withdraw than either the Eng-
lish speaking majority or minority groups.
Noting how the content of trial discussions and
researcher-defined quality of the consent were linked to
parental ethnicity or clinician attitude towards parental
ethnicity, Simon and Kodish [70] emphasise the danger of
making assumptions based on ethnicity or socio-eco-
nomic factors, which may contribute to the omission of
important information for families. However, reports that
lower SES is related to less information giving by practi-
tioners, but also to lower anxiety and a greater sense of
control among parents [59] point to competing interpre-
tations of group variations. They could represent clini-
cians' attempts to empower parents by tailoring
communication to their needs and avoiding overwhelm-
ing them with information.
While it is often reported that parents from minority
groups or disadvantaged backgrounds are less likely to
understand trials (e.g. [73-75]), little research has investi-
gated how parents from different social and ethnic groups
experience being asked to consider a trial for their child.
Research of this sort could inform efforts to meet the
needs of families from different backgrounds when they
are approached about trials.
Although qualitative research on the attitudes, under-
standing and concerns about medical research has been
conducted amongst adults in developing countries (e.g.
[76]), the authors are not aware of any qualitative studies
that report the experience of being asked to consider a ran-
domised controlled trial for a child, from the perspective
of parents in developing countries. Important questions
surround the recruitment of children to trials in develop-
ing countries and researchers conducting such trials
undoubtedly face particular challenges in managing
recruitment in societies which are more family and com-
munity orientated and less individualistic than developed
countries [76]. This represents another important gap in
the literature.
Faith and trust in medical care
Good relationships and communication between parents
and their clinician offer parents a sense of understanding,
safety and trust [59] which in turn may influence deci-
sions about trial entry [77]. Parents considering a cardiac
trial expressed a preference for the trial to be explained to
them by their cardiologist or surgeon rather than the prin-
cipal investigator or the research coordinator suggesting
that the clinical relationship provides some comfort for
families when considering trials [78]. By contrast, lack of
confidence in the doctor has been associated with
increased difficulty in decision making about trial entry
[1]. The relationship with the clinician and its impact on
the decision making process may be different across trials.
Whilst oncology and neonatology tend to see good rates
of trial participation, trial discussions in these settings
often take place within hours or days of the family's first
meeting with the clinical team suggesting that trust is not
necessarily dependent on the longevity of a relationship.
Indeed, community-based trials where families will likely
have long-standing relationships with their doctors tend
to see much lower rates of participation [37]. Evidence
that doctors who have long-standing relationships with
families fear that an approach about research might dam-
age the relationship [79] and might therefore be inclined
to present trials less favourably, throws some light on
these findings though more research is needed comparingPage 6 of 11
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interpret these patterns.
Others suggest that timing is crucial and discussing
research may seem irrelevant and even insensitive in the
immediate aftermath of diagnosis of life-threatening ill-
ness, unless handled in a way that allows families to feel
the overall care and wellbeing of the child is the clinician's
main aim [80]. But this raises yet another tension for tri-
alists to negotiate – the therapeutic misconception.
Thought to be at the centre of one of the most resilient
misunderstandings about research, the therapeutic mis-
conception describes the belief that the purpose of a clin-
ical trial is to benefit the individual patient rather than
gather data to develop scientific knowledge (National
Bioethics Advisory Commission referenced in [81]). It can
be a considerable struggle for patients and families to sep-
arate discussions about treatment options and manage-
ment from those about trial participation [82,4,10],
particularly when faced with serious illness. Adult patients
with advanced cancer interpreted their doctor's offer to
participate in a Phase 1 trial as meaning that the trial was
the right thing for them [83]. However, the therapeutic
misconception may itself be a mislabelling of the situa-
tion: a parent's hope that a child may receive a treatment
that is later shown to be better than the standard treat-
ment is not fundamentally misinformed, as this is itself
the purpose of the trial [23]. The other features of trials
such as follow-up visits and extra time spent discussing
the child's condition are often perceived by parents as
direct benefits of participation (e.g. [84-87]). Given the
complexities of trial communication when a child's life is
threatened, the therapeutic misconception does not nec-
essarily reflect a straightforward failure of the researcher to
adequately explain the research methodology or of the
parent to understand it. Indeed, it may be harmful for par-
ents to abandon the therapeutic misconception alto-
gether, as doing so could be tantamount to losing hope
and trust in medical practitioners. As Snowdon and col-
leagues suggest, where care and research become com-
pletely disconnected in people's minds, the result may be
an "injurious misconception" whereby simply being
approached about a trial triggers a disproportionate sense
of risk and threat [48].
Putting others first?
Altruism is frequently cited by researchers and parents as
a motivation for consenting to paediatric trials, but the
weight of the obligation to protect one's child means it is
unlikely that it is an overwhelming consideration when
parents are deliberating whether to enter their child in a
trial. Regardless of whether they declined or accepted, the
primary concern for parents considering an anaesthesiol-
ogy trial was the child's safety [88]. Similarly, while par-
ents believe that clinical research with children is
important, they do not necessarily wish to involve their
own children in that research [7] and their primary objec-
tive is to protect their child from harm [8]. When consid-
ering hypothetical, non-beneficial research, Reynolds and
Nelson report that parents and children would quickly
evaluate the procedural risks of a study and reject or pro-
visionally accept on that basis before considering reasons
for participation such as altruism [45]. Hence, fathers of
children with cancer were far more likely to reinforce
altruism as a reason for research participation when the
research was non-invasive but where the research
involved the child physically, altruism was not seen as a
sufficient reason for taking part [5]. Parents of children in
Phase 1 cancer trials where the benefits to others most
clearly outweigh the individual gains, spoke of 'carrying
on the fight' and 'not being ready to let go', while others
clung to the hope of a miracle cure or buying enough time
for some other treatment to become available [89].
Understandably, participating in such a trial was seen by
parents as a way to do everything they could for their
child.
Nevertheless, around two thirds of discussions between
parents and practitioners about childhood cancer trials
contained some mention of altruism, though it was usu-
ally raised by clinicians rather than families [90]. There
was no evidence that the mention of altruism affected trial
recruitment rates suggesting that it was not coercive, but a
number of other studies report altruism to be a motivating
factor for parents considering trial entry [28,91,92]. In
some cases this could be an artefact of the study design:
where people are asked retrospectively to indicate a
rationale for their actions they can endorse motivations
which construct these in a socially desirable light whilst
free of other demands. Though it is questionable how far
altruism motivates parents to include their children in tri-
als, they may use it functionally as a way of justifying their
decision after it has been made. This might be particularly
likely where a child has a poor outcome or if a child dies.
For bereaved parents, altruism may be a way of finding
some small comfort that their child might live on through
the lives of those who benefited from the trial [90], and in
this way a trial might give some kind of meaning to a loss
that otherwise seems unjust and meaningless [89]. It can
also be a way of making sense of a complex situation.
Entering a child into a trial confers no guaranteed benefit
whilst introducing an element of uncertainty into the
child's treatment. In reflecting on such a difficult decision
parents might look for some positive anchor with which
to justify what in some respects is a counterintuitive step.
It may be that the promise of benefit to a "future genera-
tion" provides such an anchor [90]. It is difficult to
uncover these nuances in how families make sense of tri-
als in studies that use questionnaires. The same criticism
applies to qualitative research which treats participants'Page 7 of 11
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rather than as constructions which need to be interpreted
in the light of the social context and functions they serve
[93,94].
Sharing responsibility with the child
We have argued that responsibility rather than autonomy
is central to understanding the situation of parents when
they are approached about trials in paediatrics. However,
parents face a new set of issues when their child is old
enough to have an opinion on whether they wish to par-
ticipate in a trial, when the need to protect one's child
might come into conflict with the child's wishes. The
available evidence indicates that parents negotiate this by
allowing the young person to have "their say" in the deci-
sion, whilst retaining responsibility for the final decision
themselves [95]. Under certain circumstances parents may
encourage or persuade children to take part in research:
parents of children who had asthma, diabetes, epilepsy or
no chronic condition who were considering hypothetical
trials [96] and mothers of children with diabetes consid-
ering entry to a real trial [84] were prepared to persuade
their child to enter a study if they believed that the bene-
fits of participation outweighed the child's fears. Particu-
larly where the child has a life-threatening illness some
parents will exclude the child from the decisions about
research altogether in order to protect them from distress-
ing information, while other parents will include the child
in discussions but make the final decision themselves
[97]. This contrasts with studies of hypothetical trials
where parents tend to report that the decision-making
process was a collaboration with their child. It is likely
that the degree of collaboration is related to the threat to
the child [7,96,98] and to the cognitive capacity of the
child [96]. Considered alongside a study examining will-
ingness to participate in hypothetical asthma trials which
suggested that adolescents were significantly more willing
than parents to enrol in above-minimal risk research [99],
this raises further complexities for paediatric trialists. The
parents' move from active participant to passive observer
in trial decisions as their child grows older is an important
area for future research [7].
Summary
• In contrast to the autonomy that typifies the situation of
adults when they are themselves approached to partici-
pate in trials, when parents are asked to consider entering
a child in a trial their decision might best be characterised
as one that embodies an obligation of responsibility.
• Some parents will see trials as a threat to their child or
fear regretting their decision, whilst others see trials as
offering hope of better treatments for their child. Almost
all parents cherish their role in protecting children and
want to secure the best outcome for them, but many are
aware of complexities of the medical and research context
and how this constrains their fulfilment of this role.
• The conduct of trials with children may benefit from a
better understanding of the special situation of parents
and their particular need for support that allows them to
retain a sense that they have safeguarded their child's
interests.
• Research is needed on how this may be realised in prac-
tice whilst observing medico-legal requirements. Thinking
of consent as a social recognition of the parental role and
aiming for 'best possible consent' may open up opportu-
nities to develop approaches to trial communication
which incorporate the flexibility for parents to construct
what is for them a meaningful understanding of the
research, as well as a meaningful exercise of parental
responsibility.
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